Immix Biopharma, Inc.
IMMXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Immix Biopharma, Inc. focuses on Biotechnology services and products. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the. The $943.3M market capitalization puts IMMX squarely in small-cap range for its industry. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Market Cap
$943.3M
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-14.50
EPS (TTM)
$-0.88
EPS (Fwd)
$-0.91
ROE
-34.2%
ROA
-20.5%
Cash
$232.1M
Total Debt
$1.0M
Free CF
-$25.4M
52W Change
535.2%
Annual Financials
Cash vs Debt
Where IMMX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMMX finished 46.95% above its 150-day moving average ($9.50) and 65.99% above its 200-day moving average ($8.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMMX overbought or oversold?
At the September 3, 2026 close, IMMX's RSI(14) was 81.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immix Biopharma, Inc. holds $232.1M in cash against $1.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$25.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -34.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.20 suggests IMMX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immix Biopharma, Inc.'s trajectory.